BlackRock Inc. increased its position in shares of Horizon Pharma PLC (NASDAQ:HZNP) by 2.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,896,831 shares of the biopharmaceutical company’s stock after acquiring an additional 266,698 shares during the quarter. BlackRock Inc. owned about 0.08% of Horizon Pharma worth $271,544,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Rothschild & Co. Asset Management US Inc. boosted its stake in Horizon Pharma by 0.6% during the 4th quarter. Rothschild & Co. Asset Management US Inc. now owns 1,662,350 shares of the biopharmaceutical company’s stock worth $32,482,000 after acquiring an additional 10,573 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its stake in Horizon Pharma by 3.2% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 946,060 shares of the biopharmaceutical company’s stock worth $18,486,000 after acquiring an additional 29,009 shares during the last quarter. Mizuho Securities USA LLC boosted its stake in Horizon Pharma by 124.1% during the 4th quarter. Mizuho Securities USA LLC now owns 60,500 shares of the biopharmaceutical company’s stock worth $1,182,000 after acquiring an additional 33,500 shares during the last quarter. Sheets Smith Wealth Management bought a new position in Horizon Pharma during the 4th quarter worth approximately $314,000. Finally, Canada Pension Plan Investment Board boosted its stake in Horizon Pharma by 15.4% during the 4th quarter. Canada Pension Plan Investment Board now owns 564,500 shares of the biopharmaceutical company’s stock worth $11,029,000 after acquiring an additional 75,500 shares during the last quarter. 88.83% of the stock is currently owned by institutional investors and hedge funds.
Shares of HZNP opened at $27.31 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.97 and a current ratio of 2.03. Horizon Pharma PLC has a twelve month low of $12.55 and a twelve month high of $29.44. The company has a market capitalization of $4.61 billion, a price-to-earnings ratio of 14.92, a P/E/G ratio of 1.49 and a beta of 1.16.
Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.54 by $0.13. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The firm had revenue of $355.50 million for the quarter, compared to analyst estimates of $334.22 million. During the same quarter in the previous year, the firm posted $0.29 earnings per share. The business’s revenue was up 29.6% on a year-over-year basis. Analysts anticipate that Horizon Pharma PLC will post 1.74 earnings per share for the current year.
Several research analysts recently weighed in on HZNP shares. TheStreet raised shares of Horizon Pharma from a “c” rating to a “b-” rating in a research note on Tuesday, November 20th. Piper Jaffray Companies set a $26.00 price objective on shares of Horizon Pharma and gave the stock a “buy” rating in a research note on Monday, January 14th. BidaskClub lowered shares of Horizon Pharma from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 20th. Jefferies Financial Group lifted their price objective on shares of Horizon Pharma to $34.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. Finally, Cowen set a $33.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, February 28th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $28.09.
In other news, EVP Geoffrey M. Curtis sold 8,835 shares of the business’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the sale, the executive vice president now owns 32,202 shares of the company’s stock, valued at $745,476.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Geoffrey M. Curtis sold 10,080 shares of the business’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $21.21, for a total transaction of $213,796.80. Following the completion of the sale, the executive vice president now directly owns 35,367 shares in the company, valued at approximately $750,134.07. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: Cryptocurrencies
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.